We are live on
!
Find out more
CASI
CASI Pharmaceuticals
CASI
CASI
Delisted
CASI was delisted on the 25th of February, 2026.
24 hedge funds and large institutions have $6.26M invested in CASI Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 11 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
14.41% more ownership
Funds ownership: 1.67% → 16.08% (+14%)
45% less funds holding
Funds holding: 44 → 24 (-20)
55% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 11
67% less capital invested
Capital invested by funds: $18.9M → $6.26M (-$12.6M)
95% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 21
Holders
24
Holders Change
-20
Holders Change %
-45.45%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
5
Reduced
11
Closed
21
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
B
Bailard
Foster City,
California
|
+$126K |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$12.2K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$8.03K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.73K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$691 |
Top Sellers
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$315K |
| 2 |
Millennium Management
New York
|
-$156K |
| 3 |
Renaissance Technologies
New York
|
-$126K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$124K |
| 5 |
BlackRock
New York
|
-$119K |
